Management strategies in unstable coronary artery disease--current problems and future directions. The UCAD Council.
Unstable coronary artery disease continues to pose a major challenge to clinicians. The advent of new therapies, such as percutaneous transluminal coronary angioplasty, low-molecular-weight heparins, and glycoprotein IIb/IIIa inhibitors, provides new management options for this indication but also raises new questions with regard to optimal management. Prospective randomized trials with well-defined, long-term outcome measures and a means of identifying which patients will derive most benefit from each treatment, together with a means of rapid and clear dissemination of study results and implications, are required in order to advance the management of unstable coronary artery disease.
Verheugt
F W
FW
Department of Cardiology, Academic Hospital Nijmegen St Radboud, The Netherlands.
Becker
R C
RC
Bertrand
M E
ME
Bode
C
C
Chesebro
J H
JH
Cleland
J G
JG
Conti
R
R
Hillis
W S
WS
Klein
W
W
Maseri
A
A
Turpie
A G
AG
Wallentin
L
L
Waters
D D
DD
D000789:Angina, Unstable / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D002309:Cardiology / Q000639:trends*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000628:therapy*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D019039:Platelet Glycoprotein GPIIb-IIIa Complex